Ibrexafungerp

111 interactions 307 cited references

Also sold as: Brexafemme Brexafemme®

About Ibrexafungerp

Ibrexafungerp is used to treat vaginal yeast infections in adults and adolescents. It is also used to reduce the number of recurrent vaginal yeast infections. Ibrexafungerp is in a class of antifungal medications. It works by stopping the growth of the fungi that cause infection. Read the full Ibrexafungerp drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Levoketoconazole Colchicine Ensitrelvir Finerenone Nafcillin Injection Dabigatran

3 Contraindicated 99 Major 9 Moderate

All (111) Contraindicated (3) Major (99) Moderate (9)

Contraindicated

Ibrexafungerp Colchicine Colcrys Increased colchicine exposure and an increased risk of colchicine toxicity Details Ibrexafungerp Ensitrelvir Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ibrexafungerp Levoketoconazole Recorlev Increased CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related adverse reaction Details

Major

Ibrexafungerp Relugolix Orgovyx Increased relugolix exposure Details Ibrexafungerp Atogepant Qulipta Increased atogepant exposure Details Ibrexafungerp Cyclosporine Injection Atopica Increased cycloSPORINE exposure Details Ibrexafungerp Cyclosporine Ophthalmic Cequa Increased cycloSPORINE exposure Details Ibrexafungerp Dabigatran Pradaxa® Increased dabigatran exposure and an increased risk of bleeding Details Ibrexafungerp Dabigatran Etexilate Increased dabigatran exposure and an increased risk of bleeding Details Ibrexafungerp Digoxin Cardoxin® Increased digoxin exposure Details Ibrexafungerp Doxorubicin Adriamycin Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Ibrexafungerp Enasidenib Idhifa Reduced antifungal exposure and reduced efficacy of antifungal agent Details Ibrexafungerp Encorafenib Braftovi Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Ibrexafungerp Finerenone Kerendia Increased finerenone exposure and an increased risk of finerenone-related adverse effects Details Ibrexafungerp Adagrasib Krazati Increased CYP3A4 substrate exposure Details Ibrexafungerp Alfentanil Increased ALfentanil exposure and an increased risk of respiratory depression Details Ibrexafungerp Apalutamide Erleada Decreased ibrexafungerp plasma concentrations Details Ibrexafungerp Artemether Increased artemether/lumefantrine exposure, an increased risk of QT prolongation, reduced CYP3A4 substrate exposure and reduced ef... Details Ibrexafungerp Atrasentan Increased atrasentan exposure and an increased risk of atrasentan-related adverse reactions Details Ibrexafungerp Avacopan Tavneos Increased CYP3A4 substrate exposure Details Ibrexafungerp Boceprevir Increased ibrexafungerp exposure Details Ibrexafungerp Bosentan Decreased ibrexafungerp plasma concentrations Details Ibrexafungerp Carbamazepine Carbatrol Decreased ibrexafungerp plasma concentrations Details Ibrexafungerp Cenobamate Xcopri Decreased ibrexafungerp plasma concentrations Details Ibrexafungerp Clarithromycin Biaxin Increased ibrexafungerp exposure Details Ibrexafungerp Cobicistat Tybost Increased ibrexafungerp exposure Details Ibrexafungerp Conivaptan Vaprisol Increased ibrexafungerp exposure Details Ibrexafungerp Cyclosporine Atopica Increased cycloSPORINE exposure Details Ibrexafungerp Dabrafenib Tafinlar Reduced sensitive CYP3A4 substrate exposure Details Ibrexafungerp Doxorubicin Hydrochloride Liposome Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Ibrexafungerp Duvelisib Copiktra Increased exposure of sensitive CYP3A4 substrates and risk of toxicity Details Ibrexafungerp Efavirenz Decreased ibrexafungerp plasma concentrations Details Ibrexafungerp Ensartinib Increased ensartinib exposure Details Ibrexafungerp Enzalutamide Xtandi Decreased ibrexafungerp plasma concentrations Details Ibrexafungerp Erythromycin Erythrocin Stearate Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse effects Details Ibrexafungerp Etravirine Intelence Decreased ibrexafungerp plasma concentrations Details Ibrexafungerp Fedratinib Inrebic Increased CYP3A4 substrate exposure Details Ibrexafungerp Fexinidazole An increased CYP3A4 substrate exposure Details Ibrexafungerp Fluconazole Diflucan Increased sensitive CYP3A4 substrates exposure Details Ibrexafungerp Fosphenytoin Cerebyx Decreased ibrexafungerp plasma concentrations Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.